Month: March 2025

SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the CardiAMP HF Trial at the Late-Breaking Clinical Trials symposium at the American College of Cardiology 2025 Scientific Sessions in Chicago (see dial-in information below). Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01)In the fourth quarter of 2024, we had a consultation...

Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) — Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2024.    Recent Highlights and AccomplishmentsCompany rebranded as Solésence, Inc., marking a new era of innovation, self-expression, and inclusivity in skin health. The move reflects the success of its consumer products strategy, fueled by its suite of transformative skin health technologies, including award-winning Kleair™. Solésence launched a new investor relations website designed to provide current and prospective investors with...

SAN JOSE, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the year ended December 31, 2024. As of December 31, 2024, the Fund’s net assets were approximately $1.1 million, or $0.15 per share, compared with net assets of approximately $1.5 million, or $0.22 per share as of September 30, 2024. As of December 31, 2024, the Fund’s portfolio included public and private securities valued at approximately $1.1 million, or $0.15 per share, which includes approximately $0.11 per share in cash and cash equivalents. Portfolio Summary (as of 12/31/24)Investment   Fair Value1, Fair Value per Share1,2Equity/Debt Investments $ 0.32 million   $ 0.05Cash/Cash...

ROCK HILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) — 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2024.Full-year 2024 revenue of $440 million, above lower end of guidance range, inclusive of a $9 million revenue reduction in Q4 driven by a change in accounting estimates for Regenerative Medicine program milestone recognition. This change in estimate is related to the now anticipated use of pre-clinical human decedent testing, successfully demonstrated by our partner, United Therapeutics, which led to refinement of the milestone technical criteria. Continued reduction in operating expenses in Q4 reflecting the company’s focus on cost savings and efficiency improvements. Announcement of a new cost reduction initiative expected to deliver over $50 million...

Exceeds first quarter revenue and profit guidance Reiterates full year guidance and remains on track to generate approximately $625 million to $650 million of adjusted free cash flow for the year Expects to return more than $240 million to shareholders in fiscal 2025 through share repurchases and dividends Ongoing momentum and demand for iX Hello™ AI productsNEWARK, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced financial results for the fiscal first quarter ended February 28, 2025.  Three Months Ended      February 28, 2025   February 29, 2024   ChangeRevenue ($M) $ 2,372.2     $ 2,402.7     (1.3)%Operating income ($M) $ 168.9     $ 148.4     13.8 %Non-GAAP operating income ($M) (1) $ 321.5     $ 319.1     0.8 %Operating...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology platform Enrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 30 patients enrolled through end of February 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumors Achieved first-in-human combination dosing of a PD-1 inhibitor with one of our potential new medicines, with recent dosing of VMT01 in combination with nivolumab IND cleared for PSV359, which targets FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. First patient dosing expected in mid-2025 Continued progress...

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced financial results for the year ended December 31, 2024, and highlighted recent corporate accomplishments. “Zentalis...